文献速递乳腺癌

淋巴结阴性HER2阳性乳腺癌辅助紫杉醇联合曲妥珠单抗试验的七年随访分析

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
PubMed 文献 · J Clin Oncol · 2019-04-02

这项II期研究纳入肿瘤≤3 cm且淋巴结阴性的HER2阳性乳腺癌患者410例,接受紫杉醇联合曲妥珠单抗治疗。中位随访6.5年,7年无病生存率为93%,总生存率为95%,远处复发4例(1.0%)。PAM50分析显示多数肿瘤为HER2富集型(66%)。

要点

  • 肿瘤≤3 cm且淋巴结阴性的HER2阳性乳腺癌患者接受辅助紫杉醇联合曲妥珠单抗,7年无病生存率为93%。
  • 中位随访6.5年,7年总生存率为95%,远处复发仅4例(1.0%)。
  • PAM50分析(n=278)显示HER2富集型占66%,管腔B型14%,管腔A型13%,基底样型8%。

核心结论

  • 随着随访时间延长,辅助紫杉醇联合曲妥珠单抗与优异的长期结局相关。
  • 小肿瘤HER2阳性乳腺癌的PAM50内在亚型分布与既往报道的大肿瘤相似。

研究设计与样本

  • II期研究,2007年10月至2010年9月共入组410例HER2阳性乳腺癌患者,肿瘤≤3 cm且淋巴结阴性。
  • 治疗方案为紫杉醇(80 mg/m2)联合曲妥珠单抗12周,随后曲妥珠单抗9个月。
  • 主要终点为无病生存期(DFS),同时分析无复发生存间期(RFI)、乳腺癌特异性生存和总生存(OS)。
  • 探索性分析对 archival 组织进行PAM50(Prosigna)内在亚型分型和复发风险评分计算,并开展基因分型探究紫杉醇诱导的周围神经毒性(TIPN)。

主要发现

  • 中位随访6.5年,共发生23例DFS事件,7年DFS为93%(95% CI,90.4至96.2),远处复发4例(1.0%)。
  • 7年OS为95%(95% CI,92.4至97.7),7年RFI为97.5%(95% CI,95.9至99.1)。
  • PAM50分析(n=278)显示HER2富集型占66%,管腔B型占14%,管腔A型占13%,基底样型占8%。
  • 基因分型(n=230)发现单核苷酸多态性rs3012437与2级及以上TIPN(10.4%)风险增加相关。

关键数值与推荐

  • 7年DFS为93%(95% CI,90.4至96.2)。
  • 7年OS为95%(95% CI,92.4至97.7)。
  • 7年RFI为97.5%(95% CI,95.9至99.1)。
  • PAM50亚型分布:HER2富集型66%,管腔B型14%,管腔A型13%,基底样型8%(n=278)。
  • rs3012437与2级及以上TIPN风险增加相关,2级及以上TIPN发生率为10.4%(n=230)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The primary analysis of the Adjuvant Paclitaxel and Trastuzumab trial demonstrated a 3-year disease-free survival (DFS) of 98.7%. In this planned secondary analysis, we report longer-term outcomes and exploratory results to characterize the biology of small HER2-positive tumors and genetic factors that may predispose to paclitaxel-induced peripheral neuropathy (TIPN). PATIENTS AND METHODS: In this phase II study, patients with HER2-positive breast cancer with tumors 3 cm or smaller and negative nodes received paclitaxel (80 mg/m2) with trastuzumab for 12 weeks, followed by trastuzumab for 9 months. The primary end point was DFS. Recurrence-free interval (RFI), breast cancer-specific survival, and overall survival (OS) were also analyzed. In an exploratory analysis, intrinsic subtyping by PAM50 (Prosigna) and calculation of the risk of recurrence score were performed on the nCounter analysis system on archival tissue. Genotyping was performed to investigate TIPN. RESULTS: A total of 410 patients were enrolled from October 2007 to September 2010. After a median follow-up of 6.5 years, there were 23 DFS events. The 7-year DFS was 93% (95% CI, 90.4 to 96.2) with four (1.0%) distant recurrences, 7-year OS was 95% (95% CI, 92.4 to 97.7), and 7-year RFI was 97.5% (95% CI, 95.9 to 99.1). PAM50 analyses (n = 278) showed that most tumors were HER2-enriched (66%), followed by luminal B (14%), luminal A (13%), and basal-like (8%). Genotyping (n = 230) identified one single-nucleotide polymorphism, rs3012437, associated with an increased risk of TIPN in patients with grade 2 or greater TIPN (10.4%). CONCLUSION: With longer follow-up, adjuvant paclitaxel and trastuzumab is associated with excellent long-term outcomes. Distribution of PAM50 intrinsic subtypes in small HER2-positive tumors is similar to that previously reported for larger tumors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tolaney SM, Guo H, Pernas S, et al. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019. PMID: 30939096. doi:10.1200/JCO.19.00066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。